Data from the first-line setting further suggest that an EGFR-based first-line therapy might create a favorable precondition for second-line treatments with VEGF-targeted antibodies [28], particularly in left-sided colon cancer [29]. This evidence concerns the gene EGFR and colonic neoplasm.